CU22629A1 - Formulaciones inmunopotenciadoras para uso vacunal - Google Patents

Formulaciones inmunopotenciadoras para uso vacunal

Info

Publication number
CU22629A1
CU22629A1 CU1997027A CU1997027A CU22629A1 CU 22629 A1 CU22629 A1 CU 22629A1 CU 1997027 A CU1997027 A CU 1997027A CU 1997027 A CU1997027 A CU 1997027A CU 22629 A1 CU22629 A1 CU 22629A1
Authority
CU
Cuba
Prior art keywords
formulation
elements
decrease
immune response
respect
Prior art date
Application number
CU1997027A
Other languages
English (en)
Inventor
Pardillo Circe Mesa
Buch Antonieta Herrera
Portilla Tania Carmenate
Perez Enrique Iglesias
Diaz Dagmara Pichardo
Ricondo Luis Javier Cruz
Martinez Maylin Diaz
Gay Maydel Hechavarria
Rio Gloria Veliz
Rubido Julio Cesar Aguilar
Angulo Maria De Jesus Leal
Pinol Juan Joel Madrazo
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1997027A priority Critical patent/CU22629A1/es
Priority to EP98907815A priority patent/EP0971737B1/en
Priority to AT98907815T priority patent/ATE295182T1/de
Priority to ES98907815T priority patent/ES2241122T3/es
Priority to DE69830156T priority patent/DE69830156T2/de
Priority to MYPI98000960A priority patent/MY132817A/en
Priority to US09/380,790 priority patent/US6355414B1/en
Priority to CA002283344A priority patent/CA2283344A1/en
Priority to AU66077/98A priority patent/AU6607798A/en
Priority to CNB988041456A priority patent/CN1161154C/zh
Priority to BR9808832-7A priority patent/BR9808832A/pt
Priority to HK00105771.4A priority patent/HK1026626B/xx
Priority to ZA981897A priority patent/ZA981897B/xx
Priority to PCT/CU1998/000003 priority patent/WO1998039032A1/es
Priority to ARP980101012A priority patent/AR009866A1/es
Publication of CU22629A1 publication Critical patent/CU22629A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con la rama de la medicina, particularmente con un nuevo adyuvante que permita la potenciación de la respuesta inmune a antígenos vacunales. El objetivo técnico que se persigue con la invención propuesta es precisamente el desarrollo de una formulación capaz de elevar los niveles de respuesta inmune del organismo a antígenos vacunales con el uso de elementos de un alto grado de pureza y que presentan una actividad sinérgica en dicha formulación. Para lograr este objetivo se emplea esencialmente una combinación de dos elementos: una sal de calcio, preferentemente el oxalato de calcio quimícamente puro y un polisacárido inmunoestimulante preferentemente el polisacárido del gel de Aloe barbadensis Miller. Otros elementos, reguladores del tamano de la partícula de oxalato de calcio, pueden ser introducidos en la formulación. La formulación objeto de esta invención, permite obtener elevadas respuestas de anticuerpos, evidenciando una actividad sinérgica reportada por primera vez entre dichas partículas y el inmunoestimulante. La diferencia entre el poder adyuvante de la formulación con respecto a los elementos por separado, es amplia. La formulación objeto de la presente invención es aplicable en la industria farmaceútica, para la elaboración de vacunas tanto para uso en humanos como en animales, a las que les confiere una mayor inmunogenicidad, permitiendo disminuir el número de inyecciones, disminuir la cantidad de antígeno por dosis y potenciar la respuesta de mucosas cuando es usada por esta vía. Además, la formulación en cuestión es factible en cualquier situación donde se desee introducir antígenos, tanto por vía mucosal como sistémica, aprovechando el vehículo o sistema particulado y las propiedades adhesivas de este compuesto con respecto a las células epiteliales.
CU1997027A 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal CU22629A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal
EP98907815A EP0971737B1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
AT98907815T ATE295182T1 (de) 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen
ES98907815T ES2241122T3 (es) 1997-03-06 1998-03-05 Formulaciones de inmunopotenciacion para uso como vacunas.
DE69830156T DE69830156T2 (de) 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen
MYPI98000960A MY132817A (en) 1997-03-06 1998-03-05 Formulations for immunological potentiation of vaccines
US09/380,790 US6355414B1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
CA002283344A CA2283344A1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
AU66077/98A AU6607798A (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
CNB988041456A CN1161154C (zh) 1997-03-06 1998-03-05 用于疫苗的免疫增强制剂
BR9808832-7A BR9808832A (pt) 1997-03-06 1998-03-05 Formulações de vacina para uso nasofarìngeo, uso mucosal e uso sistêmico
HK00105771.4A HK1026626B (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
ZA981897A ZA981897B (en) 1997-03-06 1998-03-05 Formualtions for immunological potentiation of vaccines
PCT/CU1998/000003 WO1998039032A1 (es) 1997-03-06 1998-03-05 Formulaciones inmunopotenciadoras para uso vacunal
ARP980101012A AR009866A1 (es) 1997-03-06 1998-03-06 Formulacion inmunopotenciadora para uso vacunal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal

Publications (1)

Publication Number Publication Date
CU22629A1 true CU22629A1 (es) 2000-12-22

Family

ID=5459228

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal

Country Status (14)

Country Link
US (1) US6355414B1 (es)
EP (1) EP0971737B1 (es)
CN (1) CN1161154C (es)
AR (1) AR009866A1 (es)
AT (1) ATE295182T1 (es)
AU (1) AU6607798A (es)
BR (1) BR9808832A (es)
CA (1) CA2283344A1 (es)
CU (1) CU22629A1 (es)
DE (1) DE69830156T2 (es)
ES (1) ES2241122T3 (es)
MY (1) MY132817A (es)
WO (1) WO1998039032A1 (es)
ZA (1) ZA981897B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20060105063A1 (en) * 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
AU2006238906B2 (en) 2005-04-25 2013-04-11 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
WO2008070982A1 (en) 2006-12-15 2008-06-19 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JPH08183742A (ja) * 1994-12-28 1996-07-16 Dai Ichi Seiyaku Co Ltd 経鼻ワクチンリポソーム
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
BR9808832A (pt) 2000-07-04
EP0971737A1 (fr) 2000-01-19
WO1998039032A1 (es) 1998-09-11
DE69830156T2 (de) 2006-01-26
ZA981897B (en) 1998-09-07
AU6607798A (en) 1998-09-22
ATE295182T1 (de) 2005-05-15
ES2241122T3 (es) 2005-10-16
CN1252002A (zh) 2000-05-03
DE69830156D1 (de) 2005-06-16
CN1161154C (zh) 2004-08-11
HK1026626A1 (en) 2000-12-22
MY132817A (en) 2007-10-31
EP0971737B1 (en) 2005-05-11
AR009866A1 (es) 2000-05-03
US6355414B1 (en) 2002-03-12
CA2283344A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
AU648509B2 (en) Stable vaccine compositions containing interleukins
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
DE69115514T2 (de) Liposomenhaltige intranasale Impfstofformulierung
BRPI0412444B1 (pt) fração de quil a com baixa toxidez e seu uso
ATE243530T1 (de) Virus impfstoff
Wasan et al. A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice
ES2226338T3 (es) Vacuna que comprenden interleucina 12 y antigeno del virus del herpes simple.
Zhang et al. A protein vaccine with Alum/c-GAMP/poly (I: C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern
Chand et al. Polyphosphazenes as adjuvants for animal vaccines and other medical applications
ES2853773T3 (es) Procedimientos novedosos para inducir una respuesta inmune
CU22629A1 (es) Formulaciones inmunopotenciadoras para uso vacunal
ES2894138T3 (es) Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
CN103501811B (zh) 用于治疗病毒感染的组合物和方法
Park et al. Nanoformulated single‐stranded RNA‐based adjuvant with a coordinative amphiphile as an effective stabilizer: inducing humoral immune response by activation of antigen‐presenting cells
CN100509056C (zh) 包含作为佐剂的i型ifn的疫苗和涉及它们的方法
ES2329118T3 (es) Ltb4 como adyuvante de vacuna.
EP0604727A1 (en) Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
BR0115859A (pt) Método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina
CU22740A1 (es) Formulación de ácidos nucleicos y acemanano
Phillips et al. Modulation of murine macrophage nitric oxide synthesis by liposomal phospholipids: correlation with liposome immune adjuvant activity
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
Avarvand et al. Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice
Ngu Human cancers and viruses: A hypothesis for immune destruction of tumours caused by certain enveloped viruses using modified viral antigens
Kimoto et al. Induction of systemic, mucosal and cellular immunity against SARS-CoV-2 in mice intratracheally vaccinated with a viral S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10